Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech Inc has demonstrated a positive trajectory in its clinical developments, notably through favorable data emerging from its Phase 2 studies involving Ampligen, which hold significant potential for treating post-COVID conditions and colorectal cancer. The consistent trend of positive trial results could serve as strong catalysts for future stock performance, reflecting the company's promising position in the immuno-pharmaceutical sector. With its focus on addressing unmet medical needs in various diseases, AIM ImmunoTech's robust pipeline underlines its strategic importance and potential for growth.

Bears say

AIM ImmunoTech Inc reported a net loss of $3.3 million, translating to an earnings per share (EPS) of $(1.57), which exceeded both internal and consensus estimates, indicating greater-than-anticipated operational challenges. Additionally, the company continues to face significant risks, including balance sheet and liquidity concerns, unsuccessful clinical trials, and hurdles in gaining regulatory approvals, which collectively heighten uncertainty regarding its future profitability and market position. The combination of these financial losses and operational risks contributes to a negative outlook on the company's stock.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Jan 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.